BCAL Diagnostics Limited Share Price

Equities

BDX

AU0000160921

Medical Equipment, Supplies & Distribution

Delayed Australian S.E. 03:47:17 01/05/2024 BST 5-day change 1st Jan Change
0.091 AUD -1.09% Intraday chart for BCAL Diagnostics Limited -4.21% -8.08%

Financials

Sales 2024 * 2.7M 1.75M 140M Sales 2025 * 2.5M 1.62M 130M Capitalization 23.21M 15.01M 1.2B
Net income 2024 * -4M -2.59M -207M Net income 2025 * -6M -3.88M -311M EV / Sales 2024 * 7.52 x
Net cash position 2024 * 2.9M 1.88M 150M Net cash position 2025 * 2.7M 1.75M 140M EV / Sales 2025 * 8.2 x
P/E ratio 2024 *
-5.11 x
P/E ratio 2025 *
-4.38 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 46.25%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.09%
1 week-4.21%
Current month-13.33%
1 month-13.33%
6 months-7.14%
Current year-8.08%
More quotes
1 week
0.09
Extreme 0.091
0.10
1 month
0.09
Extreme 0.091
0.12
Current year
0.09
Extreme 0.085
0.13
1 year
0.07
Extreme 0.07
0.21
3 years
0.05
Extreme 0.051
0.28
5 years
0.05
Extreme 0.051
0.28
10 years
0.05
Extreme 0.051
0.28
More quotes
Managers TitleAgeSince
Chief Executive Officer - 20/09/23
Director of Finance/CFO 70 -
Chief Tech/Sci/R&D Officer - 31/03/22
Members of the board TitleAgeSince
Director/Board Member - -
Founder - 31/12/09
Director/Board Member 75 13/02/22
More insiders
Date Price Change Volume
01/05/24 0.091 -1.09% 464 849
30/04/24 0.092 0.00% 236,385
29/04/24 0.092 -3.16% 210,016
24/04/24 0.095 0.00% 155,000
23/04/24 0.095 0.00% 110,556

Delayed Quote Australian S.E., May 01, 2024 at 03:47 am

More quotes
BCAL Diagnostics Limited is an Australia-based biotechnology company, which is focused on improving health outcomes for women. The Company’s principal activities include the development of a novel blood screening test to improve the early diagnosis and monitoring of breast cancer, including preparation for clinical trials. It developed a blood screening test to be used alongside breast cancer screening methods. The technology initially complements imaging technologies, such as the mammogram, while it further progresses the development of a monitoring and screening test suitable for women of all ages and backgrounds in any location. Its BCAL test is a lipid biomarker blood (Breast Cancer Associated Lipids test) test with the potential to be used for breast cancer prevention, screening, and monitoring. The Company has partnered with Precion Inc. to optimize protocols and procedures for the clinical studies required for regulatory approvals across several jurisdictions.
More about the company

Annual profits - Rate of surprise